Aprogen Medicines Inc. (KRX: 007460)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,020.00
-11.00 (-1.07%)
Nov 18, 2024, 3:30 PM KST

Aprogen Medicines Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2014
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2014
Cash & Equivalents
62,51035,68443,07015,89496,61671,672
Upgrade
Short-Term Investments
---4,000--
Upgrade
Trading Asset Securities
5,5005,0004,390-140,847103,191
Upgrade
Cash & Short-Term Investments
68,01040,68447,46019,894237,463174,862
Upgrade
Cash Growth
71.25%-14.28%138.57%-91.62%35.80%58.68%
Upgrade
Accounts Receivable
23,50324,80921,3891,56721,36425,170
Upgrade
Other Receivables
2,2601,6077,9889,7595,6823,738
Upgrade
Receivables
34,36734,63792,30656,990176,693133,983
Upgrade
Inventory
68,78560,81561,46723,25717,30217,403
Upgrade
Prepaid Expenses
883.17847.35913.48906.58135.72192.19
Upgrade
Other Current Assets
2,5567,2249,4322,0522,9112,716
Upgrade
Total Current Assets
174,602144,207211,578103,099434,504329,156
Upgrade
Property, Plant & Equipment
358,393362,959365,100314,47940,18666,449
Upgrade
Long-Term Investments
2,0812,4473,29854,786183,574201,170
Upgrade
Goodwill
----9.629.62
Upgrade
Other Intangible Assets
6,5357,4898,4312,6333,3553,358
Upgrade
Long-Term Accounts Receivable
----21,698-
Upgrade
Long-Term Deferred Tax Assets
--662.84-2,789-
Upgrade
Long-Term Deferred Charges
42,69734,6254,988-478274.3
Upgrade
Other Long-Term Assets
1,2081,2245,2221,90428,20646,757
Upgrade
Total Assets
626,207594,428599,853477,646834,308647,173
Upgrade
Accounts Payable
4,7492,7344,1863,9201,4211,449
Upgrade
Accrued Expenses
2,8212,5564,1178,4101,092969.54
Upgrade
Short-Term Debt
28,79824,02649,763398,61358,60076,575
Upgrade
Current Portion of Long-Term Debt
69,81367,5427,675---
Upgrade
Current Portion of Leases
663.38560.08934.882,785392.95225.93
Upgrade
Current Income Taxes Payable
115.1-4.18-874.11-
Upgrade
Current Unearned Revenue
----152.34387.55
Upgrade
Other Current Liabilities
29,55428,22223,2538,20222,56229,056
Upgrade
Total Current Liabilities
136,514125,64089,933421,92985,094108,664
Upgrade
Long-Term Debt
32,00032,00031,25131,04626,3357,598
Upgrade
Long-Term Leases
468.81288.35571.0319,925325.92554.09
Upgrade
Long-Term Deferred Tax Liabilities
8,4225,3755,3221,167-2,147
Upgrade
Other Long-Term Liabilities
1,8641,6961,455309.3926,3153,890
Upgrade
Total Liabilities
193,650176,740138,851478,453144,269129,638
Upgrade
Common Stock
139,044132,419126,834260,35191,47376,863
Upgrade
Additional Paid-In Capital
486,604472,949431,64146,794347,601270,595
Upgrade
Retained Earnings
-391,855-358,604-293,691-192,837-85,366-39,035
Upgrade
Treasury Stock
-98,115-98,115-98,084--3.6-
Upgrade
Comprehensive Income & Other
-23,591-849.6748,392-112,146-34,727-38,794
Upgrade
Total Common Equity
112,088147,800215,0922,163318,978269,630
Upgrade
Minority Interest
320,469269,888245,910-2,970371,062247,906
Upgrade
Shareholders' Equity
432,557417,688461,002-806.44690,040517,536
Upgrade
Total Liabilities & Equity
626,207594,428599,853477,646834,308647,173
Upgrade
Total Debt
131,743124,41790,195452,36985,65484,953
Upgrade
Net Cash (Debt)
-63,732-83,732-42,736-432,475151,80989,910
Upgrade
Net Cash Growth
----68.85%-
Upgrade
Net Cash Per Share
-254.56-354.54-211.16-2494.462684.941972.82
Upgrade
Filing Date Shares Outstanding
257.33244.08232.9366.3860.9851.24
Upgrade
Total Common Shares Outstanding
257.33244.08232.9366.3860.9851.24
Upgrade
Working Capital
38,08818,567121,644-318,829349,410220,493
Upgrade
Book Value Per Share
435.58605.54923.4232.595230.745261.97
Upgrade
Tangible Book Value
105,553140,311206,661-469.92315,614266,262
Upgrade
Tangible Book Value Per Share
410.19574.86887.23-7.085175.575196.25
Upgrade
Land
44,13644,13644,19012,48413,62813,628
Upgrade
Buildings
115,633115,622113,61188,04121,15920,840
Upgrade
Machinery
196,677195,122191,265137,05127,20426,467
Upgrade
Construction In Progress
111,298107,58088,23485,0171,414277.8
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.